TL033 (TFA)

• Description :

  TL033 TFA is a drug-Linker conjugates for ADC. TL033 TFA contains a linker and bioactive small molecule toxins. TL033 TFA can conjugate with Sacituzumab antibody (anti Trop-2) for synthesizing BT001021. BT001021 has anti-cancer activities against various cancers, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer[1].

• UNSPSC :

  12352005

• Target :

  Drug-Linker Conjugates for ADC

• Related Pathways :

  Antibody-drug Conjugate/ADC Related

• Field of Research :

  Cancer

• Purity :

  98.06

• Smiles :

  O=C1N2C(C3=NC4=CC=CC=C4C(CCN(C(C)C)S(C)(=O)=O)=C3C2)=CC5=C1COC([C@@]5(CC)OC(OCC6=CC=C(C=C6)NC([C@H](CCCCN)NC(COCC(NCCOCCOCCOCCOCCOCCOCCOCCOCCN7C=C(N=N7)CNC(CCCC#CC8=CN=C(S(C)(=O)=O)N=C8)=O)=O)=O)=O)=O)=O.OC(C(F)(F)F)=O.[x]

• Molecular Formula :

  C76H103N13O23S2.xC2HF3O2

• Molecular Weight :

  1630.83 (free base)

• References & Citations :

  [1]Cai Jiaqiang, et al. Bioactive conjugate, preparation method therefor and use thereof. Patent CA3080236.

• Shipping Conditions :

  Blue Ice

• Storage Conditions :

  -20°C (Powder, sealed storage, away from moisture and light)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [2746343-70-2]